MedTrace Logo

Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension

NCT04528056 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-08-27

No results posted yet for this study

Summary

Under placebo control, the investigators intend to evaluate the effectiveness and safety of anti-inflammatory therapy and/or targeted drug therapy for early treatment of patients with pulmonary arterial hypertension.

Conditions

Interventions

DRUG

Sulfasalazine

Sulfasalazine is an anti-inflammatory and immunosuppressive drug

DRUG

Ambrisentan

Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension

DRUG

Sulfasalazine's placebo

Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage

DRUG

Ambrisentan's placebo

Ambrisentan's placebo is similar to Ambrisentan in form and dosage

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Jieyan Shen, PhD · Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2021-12-31
Completion
2022-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04528056 on ClinicalTrials.gov